Bristol-Myers Squibb (BMY) trades 2.2% higher premarket after the company releases data today at...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Bristol-Myers Squibb (BMY) trades 2.2% higher premarket after the company releases data today at the European Association for the Study of Liver Disease (EASL) annual meeting showing strong data on its GS-7977 Hepatitis C candidate. At a 100% cure rate for patients, the study couldn't have produced better results.